1
0
0
(1 - 21 von 21
)
Original Article Obinutuzumab for the First-Line Treatment ...The New England Journal of Medicine
www.nejm.org
B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ... B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ...
Obinutuzumab plus bendamustine versus ...The Lancet
www.thelancet.com
... Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16) Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16)
Obinutuzumab plus bendamustine versus ...EM consulte
www.em-consulte.com
... Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver ...
Successful Drug Discovery, Volume 3google.lv
books.google.lv
... Günter Fingerle-Rowson, and Pablo Umaña Introduction 245 Preclinical Experience with Obinutuzumab 246 Characteristics and Mechanisms of Action of Type I and ...
Successful Drug Discovery, Volume 3google.it
books.google.it
... Ekkehard Mössner, Marina Bacac, Günter Fingerle-Rowson, and Pablo Umaña Introduction 245 Preclinical Experience with Obinutuzumab 246 Characteristics ...
Discovery and Development of Obinutuzumab (GAZYVA ...Wiley Online Library
onlinelibrary.wiley.com
von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ... von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ...
Obinutuzumab or Rituximab Plus Cyclophosphamide, ...Swiss Open Access Repository
sonar.ch
von U Vitolo · · Zitiert von: 420 — Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger ... von U Vitolo · · Zitiert von: 420 — Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger ...
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in ...bpspubs.onlinelibrary.wiley.com › doi › abs › bcp
bpspubs.onlinelibrary.wiley.com
· Günter Fingerle-Rowson,. Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
A Review of Obinutuzumab (GA101), a Novel Type II Anti- ...Springer
link.springer.com
von K Tobinai · · Zitiert von: 168 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ... von K Tobinai · · Zitiert von: 168 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ...
Immunochemotherapy With Obinutuzumab or Rituximab for ...Research Explorer The University of Manchester
research.manchester.ac.uk
von W Hiddemann — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ... von W Hiddemann — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ...
Obinutuzumab plus bendamustine versus ...Elsevier
mdanderson.elsevierpure.com
Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D. Cheson. Lymphoma-Myeloma. Research output: Contribution to journal ... Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D. Cheson. Lymphoma-Myeloma. Research output: Contribution to journal ...
Obinutuzumab plus bendamustine versus ...Masarykova univerzita
www.muni.cz
von LH Sehn · · Zitiert von: 371 — ... Günter FINGERLE-ROWSON and Bruce D CHESON. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non ... von LH Sehn · · Zitiert von: 371 — ... Günter FINGERLE-ROWSON and Bruce D CHESON. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non ...
Randomized Phase II Trial Comparing Obinutuzumab ...Europe PMC
europepmc.org
von LH Sehn · · Zitiert von: 179 — ... Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research ... von LH Sehn · · Zitiert von: 179 — ... Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research ...
A Review of Obinutuzumab (GA101), a Novel Type II Anti ...Figshare
adisjournals.figshare.com
posted on , 03:03 authored by Kensei Tobinai, Christian Klein, Naoko Oya, Günter Fingerle-Rowson. Article full text.
Immunochemotherapy With Obinutuzumab or Rituximab for ...The University of Manchester
research.manchester.ac.uk
... John Radford, John F. Seymour, Kensei Tobinai, Judith Trotman, Alis Burciu, Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus.
PRIME PubMed | Immunochemotherapy With Obinutuzumab or ...brain.unboundmedicine.com › medline › citation › I...
brain.unboundmedicine.com
... Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, ...
Obinutuzumab or Rituximab Plus Cyclophosphamide, ...Medpage Today
clf1.medpagetoday.com
von U Vitolo · · Zitiert von: 356 — Tatsumi, Mikkel Z. Oestergaard, Michael Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen,. Maurizio Martelli, and Laurie H.
Obinutuzumab plus bendamustine versus ...QxMD
read.qxmd.com
... Gilles Salles, John Gribben, Anne Lennard, Pieternella J Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D Cheson.
[PDF] Hypersensitivity reaction to obinutuzumab was occurred in the ...oa.mg › work
oa.mg
... John G. Gribben, Anne Lennard, Pieternella J. Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle-Rowson, Bruce D. Cheson.
Obinutuzumab for the first-line treatment of follicular lymphomaeprints.soton.ac.uk › ...
eprints.soton.ac.uk
· Author: Günter Fingerle-Rowson. Author: Kaspar Rufibach. Author: Tom Moore. Author: Michael Herold. Author: Wolfgang Hiddemann ...
Obinutuzumab for the First-Line Treatment of Follicular ...x-mol.com
www.x-mol.com
— ... Marek Trněný , Michael Wenger , Günter Fingerle-Rowson , Kaspar Rufibach , Tom Moore , Michael Herold , Wolfgang Hiddemann ...
Alle Infos zum Namen "Günter Fingerle-Rowson"
Verwandte Suchanfragen zu Günter Fingerle-Rowson
| Marcel Wolbers Andreas Meinhardt Kirsten Fischer | Philipp Lacher Clemens-Martin Wendtner Dominik Schumacher | Jörg Klug Suada Fröhlich Kaspar Rufibach |
Personen Vorname "Günter" (29119) Name |
sortiert nach Relevanz / Datum